drug · small molecule
azacitidine
Phase 2updated 5mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 8- drugOnureg21 co-mentions · 9 sources
- tagApproval12 co-mentions · 3 sources
- tagSmall Molecule8 co-mentions · 4 sources
- tagAML7 co-mentions · 2 sources
- tagOncology3 co-mentions · 2 sources
- tagDrug Shortage3 co-mentions · 3 sources
- tagPulmonology2 co-mentions · 1 sources
- drugivosidenib2 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 49 investigational indications.
targets
DNA (cytosine-5)-methyltransferase 1DNA (cytosine-5)-methyltransferase 3A
all catalysts(0)
nothing on the calendar yet
Trials studying azacitidine
- phase3A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- phase1Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- phase1A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- phase2Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
- phase2Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine
- phase1A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
- phase2A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- phase3A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
News(2)
- BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 dataBristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.fiercebiotech · 15d ago
- Dr Dinardo on the FDA Approval of Decitabine/Cedazuridine Plus Venetoclax in AMLCourtney D. DiNardo, MD, MSCE, discusses the FDA approval of decitabine/cedazuridine plus venetoclax in acute myeloid leukemia.onclive · 4mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that